These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12824197)

  • 41. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
    J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biologic therapy for rheumatoid arthritis.
    Klippel JH
    N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract]   [Full Text] [Related]  

  • 47. Rheumatoid arthritis.
    Ramsburg KL
    Am J Nurs; 2000 Nov; 100(11):40-3. PubMed ID: 11103634
    [No Abstract]   [Full Text] [Related]  

  • 48. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
    Metcalfe S; Moodie P; Grocott R; Wilkinson T
    N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
    [No Abstract]   [Full Text] [Related]  

  • 49. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 50. Interpreting registry-derived drug studies: does societal context matter?
    Kremer JM; Greenberg J
    Arthritis Rheum; 2009 Nov; 60(11):3155-7. PubMed ID: 19877064
    [No Abstract]   [Full Text] [Related]  

  • 51. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rheumatoid Arthritis - Anti-TNF.
    Chaabo K; Kirkham B
    Int Immunopharmacol; 2015 Aug; 27(2):180-4. PubMed ID: 25962818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RA treatment study group: improvement in RA management.
    Ward M; Liang MH; Burns T; Singh G
    Joint Bone Spine; 2009 Jul; 76(4):435-7. PubMed ID: 19541527
    [No Abstract]   [Full Text] [Related]  

  • 54. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract]   [Full Text] [Related]  

  • 55. Tumor necrosis factor-α inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis.
    Nishimura K; Saegusa J; Kawano S; Morinobu A
    J Rheumatol; 2012 Sep; 39(9):1904-5. PubMed ID: 22942311
    [No Abstract]   [Full Text] [Related]  

  • 56. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 57. [Focusing on the use of biologics in rheumatoid arthritis].
    Devauchelle-Pensec V; Guellec D
    Rev Prat; 2015 May; 65(5):687-8. PubMed ID: 26165113
    [No Abstract]   [Full Text] [Related]  

  • 58. Emerging therapeutics for rheumatoid arthritis.
    Bingham CO
    Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. When to initiate and discontinue biologic treatments for rheumatoid arthritis?
    Chatzidionysiou K; van Vollenhoven RF
    J Intern Med; 2011 Jun; 269(6):614-25. PubMed ID: 21261760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in use of immunomodulatory agents--a rheumatology perspective.
    Her M; Kavanaugh A
    Nat Rev Gastroenterol Hepatol; 2015 Jun; 12(6):363-8. PubMed ID: 25895821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.